David Blank Addresses Compliance Risks in Patient Support Programs in BioXconomy

AGG Healthcare partner David Blank was quoted in a BioXconomy article examining increased regulatory scrutiny of patient support programs and related compliance risks.

Federal regulators continue to evaluate whether certain program structures may implicate the Anti-Kickback Statute (“AKS”), particularly where financial assistance or support services could influence provider or patient decision-making.

David emphasized that compliance depends on careful evaluation of each program’s structure and execution. Organizations must assess both design and implementation to mitigate enforcement risk.

“Focusing on access alone can be a little problematic. All of these programs, whether they violate the Kickback Statute or they’re considered low risk,” David said at the 2026 Access USA conference. “I like to think that there is true assistance and help to the individuals, and that is laudable. That just doesn’t necessarily alleviate compliance risk.”

For life sciences companies and healthcare organizations, the article highlights the importance of proactive compliance review and documentation to support lawful program operations.

To read the full article, please click here.